FDA
-
-
-
-
-
-
-
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
-
-
-
-
-
-
-
Harrow names Frank Mullery CEO of ImprimisRx subsidiary
-
-
-
-
-
-
-
Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States
-
-
-
-
-
-
-
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
-
-
-
-
-
-
-
OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case
-
-
-
-
-
-
-
Harrow Health (HROW) Enters into 340B Prime Vendor Program Contract with Apexus for IHEEZO
-
-
-
-
-
-
-
Harrow Health (HROW) Announces Availability of VEVYE 0.1%
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

